诺和诺德Novo Nordisk (NVO) 2018年年度报告「NYSE」.pdf

1、Partnering for innovationCommitted to making obesity a healthcare priorityThe future in a tabletNovo NordiskAnnual Report 2018Management reviewLettersLetter from the chair .01Letter from the CEO .02 Introducing Novo NordiskNovo Nordisk at a glance.04Leading the Novo Nordisk Way .06Novo Nordisks corp

2、orate strategy.08Performance and outlook2018 performance and 2019 outlook.10Performance highlights .18Pipeline overview.20 Our businessPartnering for innovation.22The future in a tablet.24Committed to making obesity a healthcare priority.26In pursuit of sustainable development .28Novo Nordisks opera

3、tions.30Innovating for access in a challenging US market.32Where there are unmet needs,there is opportunity.35Taking the biopharm business above and beyond.38All references can be found on p 110.The Management review,as defined by the Danish Financial Statements Act,is found on pp 157.This Annual Re

4、port is Novo Nordisks full statutory Annual Report.See further details on p 110.The patients portrayed in this Annual Report have participated of their own accord and solely to express their personal opinions on topics referred to in the articles in which they appear,which do not necessarily reflect

5、 the views and opinions of Novo Nordisk.Use of their pictures as illustrations is in no way intended to associate them with the promotion of any Novo Nordisk products.DKK million in net salesmillion patients reached with Novo Nordisk diabetes productsGovernance,leadership and sharesResponsible busin

6、ess conduct .40Risk management enables better decision-making .41Shares and capital structure.44Corporate governance.46Board of Directors .50Executive Management .52Remuneration .53Financial,social and environmental statementsIncome statement .58Cash flow statement .59Balance sheet .60Equity stateme